Sydney Halleman / healthcaredive - The ruling maintains access to mifepristone while litigation continues. The drug can still be prescribed at pharmacies or by mail without requiring in-person visits.
AI Summary: The Supreme Court intervened to maintain access to mifepristone, temporarily restoring telehealth prescribing and preserving mail distribution while litigation proceeds. The decision keeps the pill available nationwide, blocking lower-court restrictions that would have sharply limited remote access and complicated routine clinical care for patients and providers.
Appeals court curbs mail and telehealth access to mifepristone nationwide / 29 days
Telehealth abortion pills rise as teens drive online demand / 2 months
FDA to Remove Black Box Warnings from Menopausal Hormone Therapies / 6 months
FDA updates mifepristone safety review, but pharmacies remain reluctant / 6 wks
FDA commissioner Marty Makary resigns amid mounting scrutiny / 19 days
Pennsylvania sues Character.ai over chatbot posing as licensed doctor / 24 days
Independent study flags safety issues in ChatGPT Health triage / 3 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.